TY - JOUR
T1 - A single-cell landscape of high-grade serous ovarian cancer
AU - Izar, Benjamin
AU - Tirosh, Itay
AU - Stover, Elizabeth H.
AU - Wakiro, Isaac
AU - Cuoco, Michael S.
AU - Alter, Idan
AU - Rodman, Christopher
AU - Leeson, Rachel
AU - Su, Mei Ju
AU - Shah, Parin
AU - Iwanicki, Marcin
AU - Walker, Sarah R.
AU - Kanodia, Abhay
AU - Melms, Johannes C.
AU - Mei, Shaolin
AU - Lin, Jia Ren
AU - Porter, Caroline B.M.
AU - Slyper, Michal
AU - Waldman, Julia
AU - Jerby-Arnon, Livnat
AU - Ashenberg, Orr
AU - Brinker, Titus J.
AU - Mills, Caitlin
AU - Rogava, Meri
AU - Vigneau, Sébastien
AU - Sorger, Peter K.
AU - Garraway, Levi A.
AU - Konstantinopoulos, Panagiotis A.
AU - Liu, Joyce F.
AU - Matulonis, Ursula
AU - Johnson, Bruce E.
AU - Rozenblatt-Rosen, Orit
AU - Rotem, Asaf
AU - Regev, Aviv
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Malignant abdominal fluid (ascites) frequently develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor prognosis1. To comprehensively characterize the HGSOC ascites ecosystem, we used single-cell RNA sequencing to profile ~11,000 cells from 22 ascites specimens from 11 patients with HGSOC. We found significant inter-patient variability in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations. We found that the previously described immunoreactive and mesenchymal subtypes of HGSOC, which have prognostic implications, reflect the abundance of immune infiltrates and fibroblasts rather than distinct subsets of malignant cells2. Malignant cell variability was partly explained by heterogeneous copy number alteration patterns or expression of a stemness program. Malignant cells shared expression of inflammatory programs that were largely recapitulated in single-cell RNA sequencing of ~35,000 cells from additionally collected samples, including three ascites, two primary HGSOC tumors and three patient ascites-derived xenograft models. Inhibition of the JAK/STAT pathway, which was expressed in both malignant cells and cancer-associated fibroblasts, had potent anti-tumor activity in primary short-term cultures and patient-derived xenograft models. Our work contributes to resolving the HSGOC landscape3–5 and provides a resource for the development of novel therapeutic approaches.
AB - Malignant abdominal fluid (ascites) frequently develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor prognosis1. To comprehensively characterize the HGSOC ascites ecosystem, we used single-cell RNA sequencing to profile ~11,000 cells from 22 ascites specimens from 11 patients with HGSOC. We found significant inter-patient variability in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations. We found that the previously described immunoreactive and mesenchymal subtypes of HGSOC, which have prognostic implications, reflect the abundance of immune infiltrates and fibroblasts rather than distinct subsets of malignant cells2. Malignant cell variability was partly explained by heterogeneous copy number alteration patterns or expression of a stemness program. Malignant cells shared expression of inflammatory programs that were largely recapitulated in single-cell RNA sequencing of ~35,000 cells from additionally collected samples, including three ascites, two primary HGSOC tumors and three patient ascites-derived xenograft models. Inhibition of the JAK/STAT pathway, which was expressed in both malignant cells and cancer-associated fibroblasts, had potent anti-tumor activity in primary short-term cultures and patient-derived xenograft models. Our work contributes to resolving the HSGOC landscape3–5 and provides a resource for the development of novel therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=85086776043&partnerID=8YFLogxK
U2 - 10.1038/s41591-020-0926-0
DO - 10.1038/s41591-020-0926-0
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32572264
AN - SCOPUS:85086776043
SN - 1078-8956
VL - 26
SP - 1271
EP - 1279
JO - Nature Medicine
JF - Nature Medicine
IS - 8
ER -